BHCM
JANX icon

Brevan Howard Capital Management’s Janux Therapeutics JANX Stock Holding History

Brevan Howard Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249K Sell
16,204
-8,435
-34% -$122K ﹤0.01% 1804
2026
Q1 		$342K Buy
24,639
+9,882
+67% +$136K ﹤0.01% 1538
2025
Q4 		$204K Buy
+14,757
New +$347K ﹤0.01% 1576
2025
Q1 		– Sell
-4,137
Closed -$221K – 1312
2024
Q4 		$221K Buy
+4,137
New +$219K ﹤0.01% 876

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Brevan Howard Capital Management's JANX Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Janux Therapeutics (JANX) stake by 34% in Q2 2026, selling an estimated $122K and leaving 16,204 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

Brevan Howard Capital Management first reported a position in JANX in Q4 2024 and has held it in 4 quarters since. The position peaked at $342K in Q1 2026. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Brevan Howard Capital Management held 16,204 shares of Janux Therapeutics worth $249K as of Q2 2026.
  • Brevan Howard Capital Management sold 8,435 Janux Therapeutics shares in Q2 2026, an estimated $122K.
  • Janux Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1804 holding.
  • Brevan Howard Capital Management first reported a position in Janux Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Janux Therapeutics position peaked at $342K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.